Abbott has received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan to market its Absorb bioresorbable heart stent to treat coronary artery disease.
The approval was a result of the ABSORB JAPAN clinical trial of the heart stent.
Go deeper with GlobalData
Absorb is a fully dissolving stent which is composed of a naturally dissolving material similar to dissolving sutures.
The device is completely dissolved in approximately three years, after keeping the artery unclogged, thereby allowing the treated segment to heal.
Conventional metal stents are permanent implants which inhibit vessel motion for the life of the person treated.
Kyoto University Hospital director of cardiovascular medicine and ABSORB JAPAN principal investigator professor Takeshi Kimura said: "Absorb has the potential to address the unsolved challenges of managing coronary artery disease with conventional drug eluting metallic stents.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"Our research, which involved 400 patients at 38 Japanese sites, shows that this fully dissolving stent delivered comparable results to the best-in-class Abbott XIENCE metallic drug-eluting stent on clinically important measures of safety and efficacy."
